Effects of ivermectin and its combination with alpha lipoic acid on expression of IGFBP-3 and HSPA1 genes and male rat fertility

Zeynab ElMaddawy, Walaa Slouma Hamouda Abd El Naby
In: Andrologia · 2017 · vol. 50(3) , pp. e12891 · doi:10.1111/and.12891 · PMID:28880400 · W2752712765
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

This study was conducted to evaluate the effects of ivermectin (IVM) with therapeutic dose (injected with 0.56 mg/kg b.wt.) either alone or combined with alpha lipoic acid (ALA) (50 mg/kg b.wt daily) on expression of testicular insulin-like growth factor binding protein-3 (IGFBP-3) and heat-shock protein A1 (HSPA1)) genes in the testes, as well as on male rat fertility parameters. Results revealed that expression levels of IGFBP-3 and HSPA1 were significantly increased in testis of the IVM-treated group relative to the control group. Furthermore, injection of ivermectin showed a significant decrease in serum testosterone level, sperm count, motility %, live sperm% and index weight of reproductive organs, and a significant increase in sperm abnormalities. Moreover, IVM induced oxidative stress and pathological alterations in the testes. Meanwhile, the administration of ALA with IVM prevented testicular damage and improved all previous parameters. We concluded that ivermectin has undesirable effects on male fertility and altered expression of IGFBP-3 and HSPA1 genes in the testes, while the administration of alpha lipoic acid can ameliorate the adverse effects of ivermectin.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (56)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK